MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Tome Biosciences, Inc.
Finance & Acquisitions: Tome Biosciences
Replace Therapeutics Inc.
Organization & Developments: Replace Therapeutics
Parents
Replace Therapeutics Inc.
Children
*Biotechnology company developing a novel PGI method capable of inserting and deleting small DNA sequence
In in vitro studies, L- PGI has demonstrated high efficiency and specificity in both dividing and non-dividing cells without the need for double-strand DNA breaks.
The technology combines the site-specificity of CRISPR/Cas9 with the writing enzyme DNA ligase to precisely manipulate small DNA sequences.
This ligase-mediated PGI (L-PGI) technology is well-suited for 10s to 100s of base pair DNA edits, complementing Tome’s flagship large DNA PGI technology, integrase-mediated PGI (I-PGI).
Jumps
Finance & Acquisitions: Replace Therapeutics
Key People: Replace Therapeutics